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Abstract
Background:  Pyrazinamide (PZA) is among the first-line drugs for the treatment of tuberculosis.
In vitro, it kills semidormant mycobacteria only at low pH. The purpose of this study was to
compare PZA resistance with pyrazinamidase (PZase) activity and the genotype to better
understand the molecular basis of PZA resistance and to expand the profile of pncA mutations
worldwide.
Results:  Of the 28 tested strains of Mycobacterium tuberculosis, 6 were susceptible to PZA and
positive for PZase activity and had no pncA mutations. Twenty-one strains were resistant to PZA
and negative for PZase activity and had mutations in the pncA gene, including 15 point mutations, 5
insertions, and 2 deletions. One strain had no mutation in the pncA gene, even though it was
resistant to PZA and negative for PZase activity. Three isolates had adenine to guanine point
mutations in the -11 upstream region, making this the most common type of pncA mutations in this
study, with at least two different RFLP patterns.
Conclusion:  These data help in the understanding of the molecular basis of PZA resistance. An
adenine to guanine point mutation in the -11 upstream region was the most common type of pncA
mutation in our isolates. The results of pncA mutation analyses should be carefully interpreted for
epidemiologic purposes.
Background
Pyrazinamide (PZA) is among the first-line drugs used to
treat tuberculosis. In vitro, it kills semidormant myco-
bacteria only at low pH [1]. In vitro susceptibility testing
sometimes fails because of the poor growth of mycobac-
teria at low pH. Therefore, the pyrazinamidase (PZase)
test, which was originally used for the differentiation of
Mycobacterium tuberculosis from weakly niacin-posi-
tive strains of M. bovis, has been used to identify suscep-
tible strains of M. tuberculosis, because PZase converts
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the prodrug PZA to pyrazinoic acid, the active form of the
drug [2]. The pncA gene encodes PZase, and mutations
in pncA are associated with resistance to PZA or loss of
PZase activity [3]. The purpose of this study was to com-
pare PZase activity with the genotype to better under-
stand the molecular basis of PZA resistance and to
expand the profile of pncA mutations worldwide.
Materials and Methods
Bacterial strains, PZA susceptibility and PZase activity
Twenty-eight clinical isolates of M. tuberculosis were in-
cluded. Twenty-three PZase-negative clinical isolates
were provided from Korean Institute of Tuberculosis,
and these strains had originally been collected from var-
ious sites in this country for the purpose of susceptibility
testing. Five PZase-positive isolates were collected ran-
domly among the clinical isolates grown at Pusan Na-
tional University Hospital (PNUH). The type strain M.
tuberculosis H37Rv was included as a PZA-susceptible,
and thus PZase-positive, control. All isolates were grown
in Löwenstein-Jensen medium at 37°C for 3 to 4 weeks.
The PZA susceptibility was tested by using Löwenstein-
Jensen medium at pH 5.6 with 100 and 500 µg of PZA
per mL [4]. The PZase assay was performed by the meth-
od described in the Clinical Microbiology Procedure
Handbook [2]. Briefly, 6.5 g of Dubos broth base, 0.1 g of
PZA, 2.0 g of sodium pyruvate and 15.0 g of agar were
dissolved in 1 L of distilled water and heated to dissolve
the components. The solution was dispensed in 5-mL
amounts into screw-cap tubes and stored at 2 to 8°C until
use after solidification of the agar with the tubes in an
upright position. A heavy loopful of growth from an ac-
tively growing subculture was inoculated. After incuba-
tion at 37°C for 4 or 7 days, 1 mL of freshly prepared 1%
ferrous ammonium sulfate was added to each tube. A
pink band in the agar indicated a positive test.
Genomic DNA preparation, PCR and DNA sequencing
DNA was extracted using an InstaGene matrix kit (Bio-
Rad Laboratories Inc., Hercules, CA). A 720-bp segment,
including the entire open reading frame, of the pncA
gene was amplified by using the conditions and the set of
primers P1 and P6 [5]. The PCR products were cut from
the gel and purified with the QiaAmp PCR purification
kit (QIAGEN GmbH, Germany), according to the manu-
facturer's instructions. The gel-purified PCR products
were quantitated, adjusted to a 200-µmol concentration,
and used for direct sequencing by the ABI 377 automatic
DNA sequencer (Applied Biosystems Inc., Foster, CA)
with 4 pM of each of the above-mentioned primers. The
RFLP analysis (Figure 1) was performed by an interna-
tionally standardized method for the three clinical iso-
lates showing the same pncA mutations [6], and the
hybridized membrane was detected by the colorimetric
method using the Roche digoxigenin detection kit (F.
Hoffmann-La Roche Ltd., Switzerland). The 245-bp my-
cobacterial IS probe was amplified by PCR with a DIG
DNA labeling kit (Roche) using INS-1 and INS-2 prim-
ers.
Results and discussion
All five isolates collected from our hospital were PZase-
positive and susceptible to PZA with minimal inhibitory
concentrations (MIC) of <100 µg/mL, which is consist-
ent with the initial routine tests. These isolates had pncA
sequences identical to the published sequences of pncA
Figure 1
RFLP analysis patterns of three strains containing promoter
mutations. Lane M, molecular markers; lanes 1-3, tested
strains containing -11 upstream adenine to guanine substitu-
tions; lane 4, M. tuberculosis H37Rv; lane 5, clinical isolate as a
control strain.BMC Infectious Diseases (2001) 1:4 http://www.biomedcentral.com/1471-2334/1/4
of M. tuberculosis H37Rv [3]. Among the 23 isolates col-
lected from the Korean Institute of Tuberculosis, one was
PZase-positive and susceptible to PZA (MIC <100 µg/
mL). It had no pncA mutation in the entire open reading
frame, including the upstream region. All of the remain-
ing 22 isolates were negative for PZase activity and re-
sistant to PZA (MIC >500 µg/mL). Among them, 21
organisms (96%) had mutations in the pncA gene. Elev-
en organisms had twelve point mutations, including two
point mutations in one organism, which resulted in one
silent mutation, one nonsense mutation, and 10 mis-
sense mutations. Of those, six mutations have not previ-
ously been described. One strain with a silent mutation
actually had another missense-type point mutation.
Three isolates had upstream mutations at nucleotide -11,
the single most common mutation, resulting in an ade-
nine to guanine change. One had a 3-bp insertion, result-
ing in a slipped-strand mispairing of PncA. Four had 1-
or 2-bp insertions, and two had a 2- or 234-bp deletion,
all resulting in frameshift mutations in PncA (Table 1). A
clustering tendency was apparent in that 40% (6/15) of
the point mutations were located in the region between
residues 132 and 142 of the PZase sequence. Among the
three strains with the promoter region mutations, one
isolate showed a clearly different RFLP pattern from the
other two.
The PZase test has been used for the differentiation of M.
tuberculosis from M. bovis, M. avium complex from ni-
acin-negative  M. bovis, and M. marinum from M.
kansasii [2]. The test also has been used for the detection
of PZA-resistant M. tuberculosis strains [7]. However,
the test has a shortcoming in that if old colonies are used,
false-negative results may be obtained. It seems that in
stationary- or death-phase colonies, the enzyme activity
is reduced below the limits needed to get a positive reac-
tion. This explains why one of the 23 strains that had re-
sulted in a negative PZase reaction turned out to be
PZase positive in this study.
Of the 22 PZase-negative strains, 21 (96%) showed pncA
mutations in this study. In other reports [5,8,9], pncA
mutations were found in 72% to 87% of PZA-resistant
strains and in 97% of PZase-negative strains. Sreevatsan
et al [9] suggested the possibility of another mechanism
of PZA resistance because no mutation in pncA or its up-
per promoter was found in 28% of PZA-resistant M. tu-
berculosis strains. In contrast, Hewlett et al [10]
demonstrated the low reproducibility of susceptibility to
PZA, and Scorpio et al [5] proved false resistance to PZA
in susceptible strains. So, if any other resistance mecha-
nism exists, it plays only a minor role in PZA resistance,
and more than 95% of PZA-resistant M. tuberculosis
strains likely harbor pncA mutations in this study.
Table 1: pncA nucleotide and amino acid changes in PZase-negative M. tuberculosis clinical isolates from Korea
Mutation site Nucleotide changes Amino acid changes No. of isolates
-11 A to Gb Mutation in promoter 3
23 TCG insertion Slipped-strand mispairing 1
41 G41A Missense (Cys14 Tyr) 1
56 234-bp deletion Frameshift 1
172 T172Cc Missense (Phe58 Leu) 1
190 T190G Missense (Tyr64 Asp) 1
212 A212Gd Missense (His71 Arg) 1
227 C227Te Missense (Thr76 Ile) 1
317 CT insertion Frameshift 1
382 AG insertion Frameshift 1
393 GT insertion Frameshift 1
393 T insertion Frameshift 1
395 G395T Missense (Gly132 Val) 2
403 A403Cd Missense (Thr135 Pro) 1
407 A407G Missense (Asp136 Gly) 1
421 C421T Nonsense (Gln141 Termination) 1
425, 180a C425Tf, C180T Missense (Thr142 Met), Silent (Gly60 Gly) 1
513 GC deletion Frameshift 1
a Two point mutations, including silent one, in a single strain. b Previously described mutation [4, 9, 11, 14, 16]. c Previously described mutation [16]. 
d Previously described mutations [13]. e Previously described mutation [15]. f Previously described mutation [5, 14].BMC Infectious Diseases (2001) 1:4 http://www.biomedcentral.com/1471-2334/1/4
Twenty-two mutations included single nucleotide substi-
tutions, resulting in silent, missense, or nonsense muta-
tions, and deletions and insertions of as many as 234
nucleotides. Of those, six single point mutations in seven
strains have not been described in previous studies [3, 4,
5, 9, 11, 12, 13, 14, 15, 16]. These mutations are arrayed
along virtually the entire length of the gene [9], even
though a clustering tendency was apparent in that 40%
(6/15) of the single point mutations were located in the
region between residues 132 and 142 of the PZase. The
clustering tendency in this region was described previ-
ously [5, 12]. In addition, however, we think that atten-
tion should be paid to the mutations in the promoter
region, especially the -11 upstream region. Although no
strains having this type of mutation were described in
some studies, the results of other studies, including the
present one, demonstrate that it is the most common
type of pncA mutation [4, 5, 9, 11, 13, 14, 16] (Table 2).
Moreover, most of the mutations were substitutions of
guanine for adenine. The consensus sequence TATAAT,
known as the pribnow box or -10 site, is located approx-
imately 10 bp upstream of the transcription start site of
many bacterial genes. So, it seems that mutation of the -
11 upstream site blocks binding of RNA polymerase to
the promoter site, resulting in inhibition of transcription
in the correct place. However, further experiments such
as in vitro mutagenesis should be performed to demon-
strate the relation between the promoter mutation and
loss of PZase activity. Theoretically, the same mutations
of the pncA genes would rarely be present in unrelated
isolates because mutations occur randomly along the
whole pncA gene. Therefore, pncA mutations could be a
useful tool for epidemiologic investigations. In fact,
Cheng et al reported that 21 strains having the same mu-
tations were found to be highly related by molecular typ-
ing, suggesting an outbreak from a single source [4].
However, the same mutations within a region with a
clustering tendency, such as the -11 upstream region and
the region between residues 132 and 142, do not neces-
sarily mean related strains. In the present study, one of
the strains with the promoter mutation showed an RFLP
pattern different from those of the other two, suggesting
different sources of infection. In fact, the three strains
were collected during the years 1985, 1990 and 1993, and
the two strains of the same guanine to thymine substitu-
tion at nt 395 were collected in 1990 and 1997, suggest-
ing that strains with the same mutations came from
Table 2: Type and frequency of mutations described in the pncA promoter region and the region between residues 132 and 142 of the 
PncAa
Mutation site Nucleotide change Amino acid change Frequency
-16∼ -11 AACGTA to GGCAGTT Mutation in promoter 1
-12 T to G Mutation in promoter 1
-11 A to C Mutation in promoter 1
-11 A to G Mutation in promoter 13
-7 T to C Mutation in promoter 1
394 G to A Gly132 Ser 2
395 G to A or T Gly132 Asp or Val 4
398 T to C Ile133 Thr 1
401 C to T Ala134 Val 3
403 A to C Thr135 Pro 2
406 G to C Asp136 His 1
407 A to G Asp136 Gly 1
410 A to C or G His137 Pro or Arg 4
413 G to A or C Cys138 Thr or Ser 5
415 G to C or A Val139 Leu or Met 5
416 T to C or G Val139 Ala or Gly 6
421 C to T Gln141 termination 1
422 A to C Gln141 Pro 3
424 A to C or G Thr142 Pro or Ala 2
425 C to A or T Thr142 Lys or Met 8
402∼ 403 CC insertion Frameshift 1
407∼ 408 C insertion Frameshift 1
416∼ 417 TG deletion Frameshift 1
395∼ 411 17-bp deletion Frameshift 1
a The mutations described here were cited from references [4, 5, 9, 11,12,13,14, 16] and the present studyBMC Infectious Diseases (2001) 1:4 http://www.biomedcentral.com/1471-2334/1/4
different sources. Thus, we think that pncA mutations
should be applied carefully for epidemiologic analysis.
Conclusion
These data provide a better understanding of the molec-
ular basis of PZA resistance and expand the data on pncA
mutations worldwide. Furthermore, it was demonstrat-
ed that adenine to guanine point mutations in the -11 up-
stream region are the most common type of pncA
mutations. Because of the different RFLP patterns in the
strains having the same mutations, the results of pncA
mutations should be carefully interpreted for epidemio-
logic purposes.
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